Retrospective Study of the Effects of Sub-pathologic Phenotypes of BP on Clinical Management and Prognosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

318 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-11

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bullous pemphigoid (BP) is a chronic autoimmune subepidermal blistering disease primarily affecting the elderly with a significant risk of mortality and morbidity. Various inflammatory cells such as eosinophils, lymphocytes, neutrophils and their granulopoiesis play an important role in the pathogenesis of BP. Infiltration of peripheral blood eosinophils, lymphocytes, and neutrophils into the skin is considered a major feature of BP, making it a heterogeneous disease with different histologic and clinical subtypes. This clinical study was conducted to further investigate the impact of different pathologic phenotypes of BP on the treatment and prognosis of the disease. A retrospective epidemiologic investigative approach was used，and case collection included demographic information, medical history, clinical manifestations, and histopathologic features. Including gender, age, duration of disease, number of days of hospitalization, mucosal involvement, clinical diagnosis before admission, histopathological diagnosis, laboratory tests, concomitant diseases, treatment and its changes in laboratory indexes before and after treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Identifying Factors Influencing In-Hospital Relapse in Pemphigus Patients

NCT06167408

Pemphigus Vulgaris

COMPLETED

Autoimmune Blistering Diseases Study

NCT02753777

Pemphigus Vulgaris Pemphigus Foliaceus Bullous Pemphigoid

RECRUITING

Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid

NCT03272958

Bullous Pemphigoid

COMPLETED

Prevalence of Sleep Disturbances in Bullous Pemphigoid Patients.

NCT07188402

Bullous Pemphigoid (BP)

COMPLETED

Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid?

NCT03636763

Bullous Pemphigoid

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bullous Pemphigoid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

eosinophil group

Based on the histopathologic phenotype of the patient's skin, the inflammatory cells infiltrating within and around the blisters were predominantly eosinophils

This is a retrospective analysis of health data from inpatient record, no intervention was designed

Intervention Type OTHER

This is a retrospective analysis of health data from inpatient record, no intervention was designed

neutrophil group

Based on the histopathologic phenotype of the patient's skin, the inflammatory cells infiltrating within and around the blisters were predominantly neutrophil

This is a retrospective analysis of health data from inpatient record, no intervention was designed

Intervention Type OTHER

This is a retrospective analysis of health data from inpatient record, no intervention was designed

lymphocyte group

Based on the histopathologic phenotype of the patient's skin, the inflammatory cells infiltrating within and around the blisters were predominantly lymphocyte

This is a retrospective analysis of health data from inpatient record, no intervention was designed

Intervention Type OTHER

This is a retrospective analysis of health data from inpatient record, no intervention was designed

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

This is a retrospective analysis of health data from inpatient record, no intervention was designed

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* (1) Patients with Bullous Pemphigoid who were first hospitalized in the Department of Dermatology of Xijing Hospital
* (2) Age 0-100 years old, gender is not limited.
* (3) Diagnosis is confirmed by clinical, histopathologic, immunopathologic and/or anti-BP180 antibody tests.
* (4) Complete skin histopathology information

Exclusion Criteria

* (1) Patients with Bullous Pemphigoid who were not first diagnosed in our hospital.
* (2) Those who have received systemic glucocorticoid, immunosuppressant, biologic, or other drug therapy within the past month.

Minimum Eligible Age

0 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No